Search Results for “aging” – Page 45 – media

KIHE 2024

Organiser: ITE Group Time:15 – 17 May 2024 address：42 Timiryazev str., Almaty, 050057 Almaty, Kazakhstan Exhibition hall: Atakent International Exhibition Centre Product range: Medical equipment: Medical technology equipment, laboratory equipment, medical electronic equipment, medical diagnostic equipment, ophthalmic equipment and protective products, surgical instruments, first aid and emergency equipment, hospital & Dental & medical equipment, dental service equipment and disposable medical products, hospital and home disposable medical products, hospital dentistry, medical data processing systems, dental plastic surgery, rehabilitation equipment Drugs: foreign prescription drugs, herbal preparations, mineral supplements and vitamin and other nutritional health drugs, dietary nutritional products, homeopathic preparations, dermatological preparations, maternal and infant medical care products and baby food, personal hygiene products, incontinence products, medical consumer products, cosmetics Pharmaceutical Industry: Pharmaceutical production equipment and technology, pharmaceutical packaging equipment, pharmaceutical packaging materials, pharmaceutical production, cleaning and disinfection configuration system, pharmaceutical industry raw materials and ingredients, intermediates, pharmaceutical equipment, pharmaceutical packaging, laboratory ...
- Source: drugdu
- 162
- March 11, 2024
Achieving first full year of profitability, and ushering in a new phase of high-quality development

Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited consolidated management accounts for the year ended 31 December, 2023 (the “Reporting Period”) and the information currently available to the Board, it is expected that the company will record a profit for the year of no less than RMB500 million for the Reporting Period. This is the first time for Henlius to achieve full-year profits following the company’s achievement of its first half-year profits for the six months ended 30 June 2023. The full year of profitability is primarily contributed by the continuous growth in sales revenue of the company’s core products HANQUYOU and HANSIZHUANG, as well as cost reduction and efficiency improvement through refined management. Wenjie Zhang, Chairman and Executive Director of Henlius, said: “2023 is a milestone as we reported a full-year profit for the first time. Benefiting from the efficient synergy and ...
- Source: drugdu
- 127
- March 10, 2024
AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that the latest results from three preclinical studies of the company’s novel drug candidates olverembatinib, MDM2-p53 inhibitor alrizomadlin, FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and EED inhibitor APG-5918, have been selected for presentations at the 2024 American Association of Cancer Research Annual Meeting (AACR 2024). These abstracts are now available on the AACR’s official website. The AACR annual meeting is one of the world’s largest and longest-standing scientific gatherings in the field of cancer research. Covering some of the most cutting-edge advances in all the areas of oncology research and innovation, the annual event attracts tremendous interest from the global cancer research community. This year’s AACR annual meeting will be held from April 5-10 2024, in San Diego, California, USA. These three preclinical abstracts from Ascentage Pharma include: ...
- Source: drugdu
- 99
- March 10, 2024
NHS to ensure people eligible for very high-risk breast screening are referred

Secondary breast cancer is an important risk factor after receiving radiotherapy for Hodgkin lymphoma NHS England has responded to the recent ministerial statement by newly establishing the Very High Risk (VHR) Pathway through the NHS Breast Screening Programme that invites eligible women for annual testing. The NHS is contacting 1,487 women who are at increased risk of breast cancer due to having radiotherapy involving their chest for Hodgkin lymphoma. Hodgkin lymphoma is an uncommon cancer that develops in the lymphatic system. An important risk factor after radiotherapy can include the development of secondary breast cancer, the most common cancer in the UK. Recently, the minister of state for health and secondary care, Andrew Stephenson, said in his statement that NHS England contacted a group of women who were at “very high risk of breast cancer who have been eligible for annual MRI checks, but who may not have been routinely ...
- Source: drugdu
- 151
- March 9, 2024
Simple Blood Test Could Detect Risk of Viral Infection-Induced Cardiac Arrest

Myocarditis, an inflammation of the heart often caused by the body’s immune response to a viral infection, can cause sudden cardiac death. Alarmingly, myocarditis accounts for up to 42% of sudden cardiac deaths in young adults, with viral infection being the primary cause. Traditionally, clinical understanding has focused on how inflammation affects heart rate or rhythm. Now, a new understanding from the latest research suggests completely different directions to diagnose and treat viral infections affecting the heart A new study led by scientists from the Fralin Biomedical Research Institute at Virginia Tech (Blacksburg, VA, USA) has discovered that the virus itself can create dangerous conditions in the heart even before inflammation begins. The study identified an acute phase where the virus first invades the heart, preceding the onset of inflammation due to the body’s immune response. This early infection stage sets the stage for arrhythmias before any tissue inflammation. The ...
- Source: drugdu
- 91
- March 9, 2024
【EXPERT Q&A】How is the quality inspection and quarantine carried out in the import and export industry?

Drugdu.com expert’s response: In the import and export industry, quality inspection and quarantine procedures are typically carried out by the relevant national authorities, and the process generally includes the following steps: Declaration: Importers or exporters are required to submit necessary declaration documents and information to the customs or inspection and quarantine authorities, including descriptions of goods, quantities, values, etc. This information is used for preliminary assessment and registration by customs or inspection and quarantine authorities. Inspection and Quarantine: Before goods enter or leave the port, customs or inspection and quarantine authorities conduct inspections and quarantine procedures. This involves examining the appearance, quality, quantity, packaging, etc., of the goods and conducting necessary testing, inspection, disinfection, etc. Certification Documents: Based on the inspection and quarantine results, customs or inspection and quarantine authorities issue corresponding certification documents, such as quarantine certificates, quality certificates, etc. These certification documents are usually required to be presented to ...
- Source: drugdu
- 188
- March 8, 2024
Automated Multiplexing Molecular Diagnostic Platform Revolutionizes Infectious Disease Diagnostics

A new fully automated multiplexing molecular diagnostic platform offers an innovative and cost-effective testing approach by allowing customization of tests along with the ability to process and pay for desired results, thus enabling laboratories to maximize testing efficiencies. Diasorin’s (Saluggia, Italy) new LIAISON PLEX platform provides complete flexibility for the customization of syndromic panels and helps overcome the challenge of the “one size fits all” approach faced by clinical laboratory staff for infectious disease syndromic diagnostics. Custom panels enable adjustments in response to seasonal changes and updates in clinical guidelines, helping prevent unnecessary and costly over-testing – a common issue with fixed, broad syndromic panels currently in use. The user-friendly, fully automated sample-to-answer system offers a streamlined workflow and room-temperature stable consumables, simplifying storage and transport logistics. Additionally, it requires just two minutes of hands-on time per sample and can deliver results in less than two hours. The LIAISON PLEX, ...
- Source: drugdu
- 142
- March 8, 2024
Researchers develop brain-age prediction tool for diagnosis of neurological diseases

The non-invasive tool can also improve patient stratification and monitor disease progression Researchers from King’s College London (KCL) have developed a deep learning framework for a non-invasive brain-age prediction tool for the early diagnosis of neurological diseases. The study built and made available a set of models for clinical use after training multiple brain models from a variety of magnetic resonance image (MRI) types. Neurological disorders, such as Alzheimer’s disease, strokes, multiple sclerosis and Parkinson’s disease, are conditions that affect the brain as well as the nerves found throughout the human body and spinal cord. By comparing patients’ brain ages against their chronological ages, numerous neurological and psychiatric conditions can be identified, helping to predict future health outcomes for patients. Researchers collected over 81,000 patients’ head MRI examinations from Guy’s and St Thomas’ NHS Foundation Trust and King’s College Hospital NHS Foundation Trust between 2008 and 2019. After pre-training models, ...
- Source: drugdu
- 89
- March 7, 2024
Groundbreaking Blood Test Offers Early Pancreatic Cancer Diagnosis

Pancreatic cancer ranks as the third leading cause of cancer-related deaths, primarily due to its late detection. Early discovery of the disease, while it’s still treatable, could significantly impact survival rates. For more than a century, scientists have sought to link cancer with cellular energy production and metabolism. The advent of quantitative mass spectrometry has enabled the testing of many such theories. Now, for the first time, researchers have utilized targeted mass spectrometry to demonstrate that pancreatic cancer stems from changes in cellular metabolism that are detectable using a simple blood test. This method could lead to more precise and earlier diagnoses of pancreatic cancer than currently possible with tumor markers or imaging techniques, potentially paving the way for more timely and appropriate therapeutic interventions. In contrast to genomic approaches that measure DNA for early detection and often struggle with false positives and negatives, mass spectrometry can measure extremely low ...
- Source: drugdu
- 173
- March 6, 2024
【EXPERT Q&A】How to distinguish a class, Class II, Class III medical devices?

Drugdu.com expert’s response: Medical devices are typically classified into different categories, including Class I, Class II, and Class III, based on their level of risk and intended use. Here is a general overview of how these categories are distinguished: Class I Medical Devices: Class I medical devices are generally considered to have low risk and may have little or no impact on the human body. They typically do not require specialized regulatory controls.These devices include simple, non-invasive devices such as thermometers, disposable gloves, non-invasive blood pressure monitors, etc. Class II Medical Devices: Class II medical devices pose higher risks compared to Class I devices and may have a moderate impact on the human body, requiring stricter regulatory controls.Examples of Class II devices include diagnostic equipment, infusion pumps, medical imaging devices, implantable medical devices, etc. Class III Medical Devices: Class III medical devices carry the highest level of risk and may cause ...
- Source: drugdu
- 169
- March 5, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.